Mesenchymal Stem Cells Clinical Trial
Official title:
Adipose-tissue Derived Stem Cells: Characterization of Adipose-tissue Derived Stem Cells in Flaps Versus Liposuction
Verified date | February 2017 |
Source | University of Aarhus |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of the study is to evaluate a physiological concentration of adipose tissue-derived stem cells (ASC) in excised fat versus fat harvested by liposuction. Participants will act as their own control as both extraction methods are performed on each participant.
Status | Completed |
Enrollment | 20 |
Est. completion date | August 31, 2017 |
Est. primary completion date | August 31, 2017 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Eligible women - over the age of 18 - Deemed suitable for abdominoplasty with abdomen pendens, fleur de lis, panniculectomy or belt lipectomy. - Able to read and understand Danish Exclusion Criteria: - Current smokers - patients not having paused for a minimum of four weeks prior to surgery. - Prior or current adjuvant chemo therapy |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Aarhus |
Bourin P, Bunnell BA, Casteilla L, Dominici M, Katz AJ, March KL, Redl H, Rubin JP, Yoshimura K, Gimble JM. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). Cytotherapy. 2013 Jun;15(6):641-8. doi: 10.1016/j.jcyt.2013.02.006. Epub 2013 Apr 6. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Stem cell yield | Stem cell yield measured by antibody stained flow cytometry. | At baseline right after isolation. | |
Primary | Stem cell yield | Stem cell yield measured by colony forming units and number of colonies >50 cells are counted. | Cells are cultured from baseline to day 14. | |
Secondary | Growth kinetics | Growth kinetics measured by culturing. The population doubling time is determined using log phase of growth | Cultured for 7 days and counted. | |
Secondary | Adipogenic, chondrogenic and osteogenic differentiation. | Differentiation assays for adipogenic, chondrogenic and osteogenic differentiation with Oil Red O staining, Safranin O staining and Alizarin red S staining. | Through study completion, an average of 1 year. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01219465 -
Umbilical Cord Mesenchymal Stem Cells Infusion for Initial Type 1 Diabetes Mellitus
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01221428 -
Umbilical Cord Mesenchymal Stem Cells Infusion for Ulcerative Colitis
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT01224327 -
Umbilical Cord Mesenchymal Stem Cells Infusion Via Hepatic Artery in Cirrhosis Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT06149832 -
Treatment of Oral Chronic Graft-versus-host Disease With Human Umbilical Cord Mesenchymal Stem Cell Dressing
|
Phase 4 | |
Recruiting |
NCT05165459 -
Open Label Single Arm Proof of Concept Trial to Evaluate the Efficacy and Safety of Cytori Celution System in Chronic Non-Healing Venous Leg Ulcers
|
N/A | |
Active, not recruiting |
NCT04014166 -
Study of Human Umbilical Cord-derived Mesenchymal Stem Cells for Treatment of Refractory Immune Thrombocytopenia
|
N/A | |
Not yet recruiting |
NCT06077734 -
Muscle Stem Cell Quality in Atrophy
|
||
Completed |
NCT00956891 -
Therapeutic Effects of Liver Failure Patients Caused by Chronic Hepatitis B After Autologous MSCs Transplantation
|
Phase 1/Phase 2 | |
Recruiting |
NCT01218464 -
Safety and Efficacy of Human Mesenchymal Stem Cells for Treatment of Liver Failure
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03874572 -
Allogeneic Mesenchymal Stem Cells for Radiation-induced Hyposalivation and Xerostomia/Dry Mouth
|
Phase 1 | |
Recruiting |
NCT00953485 -
Allogeneic Mesenchymal Stem Cells Transplantation for Primary Sjögren's Syndrome (pSS)
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04863183 -
Cell Therapy With Cellistem-OA for Symptomatic Knee Osteoarthritis
|
Phase 1/Phase 2 | |
Completed |
NCT06360861 -
Evaluate the Safety and Feasibility of Allogeneic Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1 | |
Completed |
NCT05018754 -
Treatment of Oral Mucositis Using Platelet Rich Fibrin TREATMENT OF ORAL MUCOSITIS USING PRF
|
||
Recruiting |
NCT04356287 -
Treatment With Human Umbilical Cord-derived Mesenchymal Stromal Cells in Systemic Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT03130374 -
Treatment of Laryngotracheal Stenosis Using Mesenchymal Stem Cells
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02673788 -
Follow-Up Study of Safety of Pneumostem® in Premature Infants With Intraventricular Hemorrhage
|
||
Recruiting |
NCT01763099 -
Mesenchymal Stem Cells Combined With Cord Blood for Treatment of Graft Failure
|
Phase 2 | |
Recruiting |
NCT01763086 -
Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplant
|
Phase 2 | |
Completed |
NCT02302599 -
Mesenchymal Stem Cells to Treat Type 2 Diabetes
|
Phase 2 |